首页> Future oncology (London, England)> E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors-design and rationale.

E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors-design and rationale.

导出 OA

翻译打印收藏纠错

第一作者： Elias B A,Chandran

第一单位： Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

作者： Elias B A,Chandran ^[1] ; Saad,Atiq ^[1] ; Nicholas,Simon ^[1] ; Daniel,Girardi ^[1] ; Lisa,Ley ^[1] ; Lisa,Cordes ^[1] ; Ruchi,Patel ^[1] ; Tzu-Fang,Wang ^[1] ; Andre R,Kydd ^[1] ; Bernadette,Redd ^[1] ; Salah,Boudjadi ^[1] ; Ian,Stukes ^[1] ; Rouf,Banday ^[1] ; Elizabeth,Smith ^[1] ; Dilara,Akbulut ^[2] ; Scot,Niglio ^[3] ; Sandeep,Gurram ^[4] ; Seth,Steinberg ^[5] ; Andrea B,Apolo ^[1]

作者单位： Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. ^[1] Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. ^[2] Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA. ^[3] Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. ^[4] Office of Collaborative Biostatistics, Office of the Clinical Director, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. ^[5]

关键词 Rare genitourinary tumors antibody-drug conjugates bladder adenocarcinoma bladder squamous cell carcinoma enfortumab vedotin pembrolizumab refractory testicular cancer urachal adenocarcinoma

医学主题词女(雌)性(Female);人类(Humans);男(雄)性(Male);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);泌尿生殖系统肿瘤(Urogenital Neoplasms);临床试验, Ⅱ期(主题)(Clinical Trials, Phase II as Topic)

DOI 10.1080/14796694.2025.2497719

PMID 40421891

发布时间 2025-06-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交